Latest Clinical Trial for Pleural Mesothelioma Opens in Georgia

This study is open also to patients with lung cancer or urothelial cancer. In the trial, the use of cabozantinib will be combined with standard-of-care Alimta, the chemotherapy drug generically known as pemetrexed. The study is designed to establish a safe and effective dosage level for both agents when used together. Cabozantinib is known as an inhibitor. It blocks signals that encourage the growth of new blood vessels needed for cancer cells to divide and grow. Blocking those signals can shrink tumors or even cause tumor cell death, leading to significantly longer survival for patients. Cabozantinib will be taken orally on a daily basis, with gradually increasing dosage levels. The intravenous chemotherapy will be given every 21 days, involving four cycles. “Right now, there is very little out there, very few treatment options, for mesothelioma patients,” Karim said. “The scientific rational for this combination is a good one.” New Drug Combinations Key to Advancing Mesothelioma Treatment There is no cure for mesothelioma cancer, which is caused almost exclusively by exposure to asbestos. Fewer than half of patients diagnosed with pleural mesothelioma live more than a year. The most effective treatment includes a combination of aggressive surgery, chemotherapy and radiation. One problem, however, is that less than a third of those diagnosed even qualify for surgery because the cancer already is too advanced. Early symptoms are difficult to identif...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Patients with pleural mesothelioma cancer may have another treatment option after the U.S. Food and Drug Administration approved the use of pembrolizumab for certain metastatic tumors this week. Pembrolizumab, often known by the brand name Keytruda, is a well-known immunotherapy drug already being used with mixed success for several cancers. This latest FDA approval is for the treatment of adult and pediatric cancers with unresectable disease and high mutational burden that have progressed following prior treatment and have no alternative treatment options. A number of mesothelioma patients already are being treated with p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusions: Since its introduction, PERCIST 1.0 has been increasingly used in many clinical trials and prospective studies, with variable reporting of metabolic response and survival data. In general, it appears PERCIST response is associated with longer PFS and survival though the heterogeneity of disease, scan timing and therapies make data pooling difficult. Prospective inclusion of the PERCIST 1.0 criteria in clinical trials using FDG, with baseline, early monitoring, and end of therapy scans could inform cancer clinical trials. Support: 5U01CA140204-04 Reference: 1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: NET and Others II Source Type: research
Publication date: Available online 10 January 2020Source: Pathology - Research and PracticeAuthor(s): Masanori Matsuda, Hironori Ninomiya, Ryo Wakejima, Kentaro Inamura, Sakae Okumura, Mingyon Mun, Masanobu Kitagawa, Yuichi IshikawaAbstractCalretinin, a mesothelioma marker, is sometimes expressed in lung cancer, which may complicate the differential diagnosis of mesothelioma. Here, the clinicopathological and immunohistochemical characteristics of calretinin-positive lung cancer were examined to reduce confusion with malignant mesothelioma. Calretinin expression in 307 consecutive cases of lung cancer was evaluated immunoh...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
President Donald Trump on Monday signed legislation that will extend the September 11th Victim Compensation Fund until 2092. During the signing ceremony at the White House, Trump was surrounding by first responders, survivors and family members of several who died in the 2001 terrorist attack on the United States. The U.S. House of Representatives and the U.S Senate voted overwhelmingly last week to approve the legislation that will provide a lifetime of assistance for victims and their families. The extension will allow the fund, first established in 2001, to pay for past and future medical claims of those effected by the...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The U.S. Senate followed the House of Representatives on Tuesday and passed legislation that will extend the September 11 Victim Compensation Fund until 2092. The legislation will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania. The extension of funding will benefit victims who may develop mesothelioma linked to the more than 400 tons of asbestos that covered the 16-acre disaster zone after the twin towers fell. According to World Trade Center R...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The Senate gallery erupted in applause from politicians and first responders on Tuesday after a 97-2 vote to extend the September 11 Victim Compensation Fund until 2092. The reauthorization will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania. The extension will allow victims and their families to file claims through 2090, but they will be paid out through 2092. The extension of funding will benefit victims who may develop mesothelioma linked to ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurposeImmune-checkpoint inhibitors have shown great efficacy in clinical oncology and a very safe toxicity profile. Nevertheless, endocrine toxicity and, in particular, thyroid diseases are among the most frequently reported adverse events. The aim of this study was to assess the utility of a complete endocrine evaluation before starting therapy, in order to predict which patients will develop a thyroid disease and will need a close follow-up.MethodsTwenty-eight patients were treated with ipilimumab and nivolumab for non-small-cell lung cancer or malignant pleural mesothelioma. All patients underwent complete endo...
Source: Endocrine - Category: Endocrinology Source Type: research
This study aimed to explore whether a correlation exists between the incidence and mortality of cancers and normalized internet search volumes on the big data platform, Baidu. We also assessed whether the distribution of people who searched for specific types of cancer differed by gender. Finally, we determined whether there were regional disparities among people who searched the Web for cancer-related information. Methods: Standard Boolean operators were used to choose search terms for each type of cancer. Spearman’s correlation analysis was used to explore correlations among monthly search index values for each can...
Source: Journal of Medical Internet Research - Category: General Medicine Authors: Source Type: research
Conclusion: pleural ultrasonic elastography is a valuable and effective technique in differentiating MPE from benign pleural effusion and may become an important adjunct in diagnostic methods.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: 11.2 Pleural and Mediastinal Malignancies Source Type: research
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Georgia Health | Immunotherapy | Liver | Lung Cancer | Mesothelioma | Study | Thyroid | Thyroid Cancer | Urology & Nephrology